

66/60/90
JC604 U.S. PTO

Box: PATENT APPLICATION
Assistant Commissioner for Patents
Washington, DC 20231

Attorney's Ref: UCON/141/US
Date: June 9, 1999

A
JC525 U.S. PTO
09/328742
06/09/99

Sir:

Transmitted herewith for filing is the (X) utility () design patent application of
Inventor(s): Alexandros Makriyannis, Sonyuan Lin and Daniele Piomelli
For: Inhibitors of the Anandamide Transporter as Analgesic Agents

Enclosed are:


- (X) 5 sheets of () formal (X) informal drawings.
- () An assignment of the invention to _____.
- () A certified copy of a _____ application.
- (X) An unsigned Inventors' Declaration and power of attorney.
- () A verified statement claiming small entity status.
- () A preliminary amendment.

The filing fee has been calculated as shown below:

- () design application for () small entity = \$155 () not small entity = \$310
- (X) utility application

	No. Filed	No. extra	Small Entity Rate	Fee	Not Small Entity Rate	Fee
Basic Fee				\$380	OR	\$760
Total Claims	20	- 20 = 0	x 9 =		OR x 18 =	
Indep. Claims	3	- 3 = 0	x 49 =		OR x 78 =	
Multiple Dependent Claims Presented			+ 130 =		OR + 260 =	
			TOTAL =		TOTAL =	\$760

- (XX) A check in the amount of \$ 760.00 to cover the filing fee is enclosed.
- () Please charge my Deposit Account No. 16-2563 in the amount of \$_____ to cover the filing fee.
A duplicate of this sheet is enclosed.
- (XX) The Commissioner is hereby authorized to charge any additionally required filing fees under 37 CFR 1.16 associated with this communication or credit any overpayment to Deposit Account No. 16-2563. A duplicate copy of this sheet is enclosed.
- () The Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 required during the pendency of this application and to credit any overpayment to Deposit Account No. 16-2563. A duplicate copy of this sheet is enclosed.


James E. Alix, Reg. No. 20,736
Alix, Yale & Ristas, LLP
750 Main Street
Hartford, CT 06103-2721
Telephone: (860) 527-9211

EXPRESS MAIL mailing label number EL 093 168 686 US

I, Kathleen C. Stuart, hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on June 9, 1999, and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.



Inhibitors of the Anandamide Transporter as Analgesic Agents

Government Funding

This invention was made with Government support under Contract No. DA 3801 awarded by the National Institute of Drug Abuse. The Government has certain rights in the invention.

Related Application

This application is based on and claims the benefit under 35 U.S.C. §119(e) of United States Provisional Application No. 60/088,568 filed June 9, 1998.

Background of the Invention

The marijuana derived cannabinoid Δ^9 -tetrahydrocannabinol, Δ^9 THC, is known to bind to CB1 receptors in the brain and CB2 receptors in the spleen. Compounds which stimulate those receptors have been shown to induce analgesia and sedation, to cause mood elevation including euphoria and dream states, to control nausea and appetite and to lower intraocular pressure. Cannabinoids have also been shown to suppress the immune system. Thus, compounds which stimulate the receptors, directly or indirectly, are potentially useful in treating glaucoma, preventing tissue rejection in organ transplant patients, controlling nausea in patients undergoing chemotherapy, controlling pain and enhancing the appetite and controlling pain in individuals with AIDS Wasting Syndrome.

66090-44880

EL 093 168 686 45

In addition to acting at the receptors, cannabinoids also affect cellular membranes, thereby producing undesirable side effects such as drowsiness, impairment of monoamine oxidase function and impairment of non-receptor mediated brain function. The addictive and psychotropic properties of cannabinoids also limit their therapeutic value.

Arachidonyl ethanolamide (anandamide) is an endogenous lipid that binds to and activates cannabinoid receptors and mimics the pharmacological activity of Δ^9 THC. In general, anandamide has been found to be somewhat less potent than Δ^9 THC. Despite having a rapid onset of action, the magnitude and duration of action of anandamide is relatively short, presumably because of a rapid inactivation process consisting of carrier-mediated transport into cells followed by intra-cellular hydrolysis by a membrane-bound amidohydrolase, anandamide amidase. Thus, inhibitors of anandamide amidase have the effect of indirectly stimulating the receptors by increasing *in vivo* levels of anandamide. In this connection, attention is directed to Makriyannis et al U.S. Patents 5,688,825 and 5,874,459, the disclosures of which are incorporated herein by reference.

Anandamide released by depolarized neurons is believed to be subject to rapid cellular uptake followed by enzymatic degradation. Indeed, rat brain neurons and astrocytes in primary culture avidly take up radioactively labeled anandamide through a mechanism that meets four key criteria of a carrier-mediated transport; temperature dependence, high affinity, substrate selectivity, and saturation. In that other lipids

including polyunsaturated fatty acids and prostaglandin E₂ (PGE₂) enter cells by carrier-mediated transport, it is possible that anandamide uses a similar mechanism. This accumulation may result from the activity of a transmembrane carrier or transporter, which may thus participate in termination of the biological actions of anandamide. This carrier or anandamide transporter is believed to be involved in the inactivation of anandamide. Thus, anandamide released from neurons on depolarization may be rapidly transported back into the cells and subsequently hydrolyzed by an amidase thereby terminating its biological actions. Consequently, the anandamide transporter is a potential therapeutic target for the development of useful medications.

There is considerable interest in understanding the mechanism of anandamide transport and in developing pharmacological agents that selectively interfere with it. Anandamide transport inhibitors may be used as experimental tools to reveal the possible physiological functions of this biologically active lipid. Many of these functions are still elusive despite a growing body of evidence suggesting that the endocannabinoid system is intrinsically active not only in brain and spinal cord, but also in peripheral tissue. Furthermore, anandamide transport inhibitors may offer a rational therapeutic approach to a variety of disease states, including pain, psychomotor disorders, and multiple sclerosis, in which elevation of native anandamide levels may bring about a more favorable response and fewer side effects than direct activation of CB1 receptors by agonist drugs.

Summary of the Invention

It has now been found that certain analogs of anandamide are potent inhibitors of transport of anandamide across cell membranes. The transport inhibitor does not activate the cannabinoid receptors or inhibit anandamide hydrolysis *per se* but instead prevents anandamide reuptake thereby prolonging the level of the undegraded anandamide. Previously, cannabinoid drugs were targeted toward cannabinoid receptors and amidase enzymes. The anandamide transport inhibitor of the present invention targets activity of the anandamide transporter.

The inhibitors are amide and ester analogs of anandamide and exhibit the tail, central and head pharmacophore portions represented by Structural Formula I



wherein tail portion X is a fatty acid chain remnant, central portion Y is an amide or ester radical and head portion Z is selected from the group consisting of hydrogen, alkyl, hydroxy alkyl, aryl, hydroxy aryl, heterocyclic and hydroxy heterocyclic radicals.

The novel inhibitors of the present invention, when tested *in vitro*, inhibit accumulation of anandamide in rat cortical neurons and astrocytes and enhance various effects of anandamide administration both *in vitro* and *in vivo*. The vasodepressor responses are significantly potentiated and prolonged by the transport inhibitors. Thus, the inhibitors are believed to be effective drugs for the treatment of cardiovascular diseases and blood pressure disorders.

The novel biochemical pathway involving the anandamide transporter system and composition disclosed herein have other therapeutic uses. For example, the compounds and methods of the present invention, like cannabinoids, can be effective in the relief of the pain caused by cancer and the nausea resulting from cancer chemotherapy. Beneficially, they would not be expected to have the undesirable membrane-related side-effects associated with cannabinoids. In addition, the methods and compounds disclosed herein may be immunosuppressive and can therefore be used to prevent organ rejection in an individual undergoing an organ transplant. Because the compounds and methods of the present invention enhance the appetite of an individual, they can be used to treat patients with AIDS Wasting Syndrome, who are often suffering from malnourishment as a result of appetite loss. The compounds could also be used to combat Kinetic disorders and peripheral hypertension.

The novel inhibitors of anandamide transport disclosed herein also have research uses. For example, they can be used to maintain the level of anandamide *in vivo* to study the effect of anandamide on individuals and animals. The anandamide transport inhibitors disclosed herein can also be used as an aid in drug design, for example as a control in assays for testing other compounds for their ability to inhibit anandamide transport and to determine the structural and activity requirements of such inhibitors. These results, together with data from initial experiments on the selectivity of radioactively labeled [³H]anandamide uptake by rat brain astrocytes, suggest that the interactions of anandamide with its putative transporter protein are governed by strict

structural requirements. These results delineate the broad molecular requisites for this process, thus providing a basis for the design of more potent and selective inhibitors with potential applications to medicine.

Anandamide uptake in neurons and astrocytes has been found to be mediated by a high-affinity, Na^+ -independent transporter that is selectively inhibited by the inhibitors of the present invention. The structural determinants governing recognition and translocation of substrates by the anandamide transporter have been determined. The results show that substrate recognition by the transporter is favored by a polar nonionizable head group of defined stereochemical configuration containing a hydroxyl moiety at its distal end. The secondary amido group interacts favorably with the transporter, but may be replaced with either a tertiary amide or an ester, suggesting that it may serve as hydrogen acceptor. Putative endogenous cannabinoid esters also serve as a substrate for the transporter. Substrate recognition and translocation require the presence of at least one cis double bond situated at the middle region of the fatty acid hydrocarbon chain, indicating a preference for ligands whose hydrophobic tail can adopt a bent U-shaped or hair-pin configuration. Uptake experiments with radioactively labeled substrates favor two or more and preferably four cis nonconjugated double bonds for optimal translocation across the cell membrane, suggesting that substrates are transported in a folded hairpin conformation.

Brief Description of the Figures

Fig. 1 is a graph showing the effect on adenylyl cyclase activity in the presence of anandamide alone and in combination with the transporter inhibitor.

Fig. 2 is a graph showing the effect of anandamide transport inhibitors on adenylyl cyclase activity.

Fig. 3 is a graph showing the effect of the transporter inhibitor on the analgesic activity of anandamide in the hot plate test.

Fig. 4 is a graph showing the translocation of substrate inhibitors of the present invention.

Fig. 5 is a graph showing the effect of the number of cis double bonds on translocation.


Detailed Description of the Invention

One embodiment of the present invention is directed to the discovery of a putative anandamide transporter system which can be used as a target for the discovery of novel medications. These would include all compounds that can inhibit the function of this transporter. The invention further includes the pharmacological formula containing an effective amount of the inhibitor while another embodiment is directed to a method of inhibiting anandamide transport in an individual or animal by administering a therapeutically effective amount of the inhibitor and/or physiologically acceptable salts thereof. The inhibition results in increased levels of anandamide in the

individual or animal, thereby causing prolonged stimulation of cannabinoid receptors in the individual or animal, e.g., the CB1 receptor in the brain and the CB2 receptor in the spleen. Thus, the present invention involves not only the inhibitor itself but also a method of reducing anandamide transporter activity in an individual or animal. It is to be understood that the present invention may also be used to reduce the activity of transporters not yet discovered for which anandamide and/or a cannabinoid act as an agonist.

The anandamide transport inhibitors of the present invention are amide and ester analogs of anandamide having the three pharmacophores of the Structural Formula I wherein the tail portion X is a fatty acid hydrophobic carbon chain having one or more nonconjugated cis double bonds in the middle portion of the aliphatic hydrocarbon chain. The chain may contain four to thirty carbon atoms but preferably the chain length is about 10 to 28 carbon atoms and more preferably contains from about 17 to about 22 carbon atoms. By contrast, analogs with fully saturated chains or with a trans or terminal double bond fail to compete successfully with [³H]anandamide for transport and thus are ineffective as inhibitors. The central pharmacophore Y is selected from the group consisting of amide and ester radicals. Conversely, compounds containing a free carboxylic acid, carboxyethyl and carboxymethyl groups, or a primary alcohol are inactive. The head portion Z is selected from the group consisting of hydrogen, lower alkyl, hydroxy substituted lower alkyl, aryl, hydroxy substituted aryl, heterocyclic and hydroxy substituted heterocyclic radicals.

As used herein, "aliphatic hydrocarbon" includes one or more polyalkylene groups connected by one or more *cis*-alkenyl linkages such that the total number of methylene carbon atoms is within the ranges set forth herein. The structure of preferred tail portions have the formula II



wherein R is selected from the groups consisting of hydrogen and lower alkyl groups, a and c are integers 0 and 1 through 10 and b is an integer from 1 through 6. Specific examples include structures where X is CH₃ - (CH₂)₄ - (cis-CH=CHCH₂)₄ - (CH₂)₂-, CH₃ - (CH₂)₄ - (cis-CH=CHCH₂)₃-(CH₂)₅-, CH₃ - (CH₂)₆ - (cis-CH=CHCH₂)₂ - (CH₂)₆ -, CH₃ - (CH₂)₆ - (cis-CH=CHCH₂)₂ - (CH₂)₅ - CH₃-(CH₂)₇-cis CH=CH-(CH₂)₉, CH₃ - (CH₂)₇ - cis - CH=CH-(CH₂)₇ - and CH₃-(CH₂)₄-(CH=CHCH₂)₄-CH₂-C(CH₃)₂-. A lower alkyl group is a straight or branched chain alkyl group having 1 to 5 carbon atoms.

As used herein, an "aryl" group is a carbocyclic aromatic ring system such as phenyl, 1-naphthyl or 2-naphthyl.

As used herein, a "heterocyclic" group is a non-aromatic ring system of 4 to 8 carbon atoms containing one or more heteroatoms such as oxygen or nitrogen with the amido nitrogen forming part of the ring structure. Examples include pyrrolidinyl and piperidinyl groups.

All amides may be synthesized by the reaction of the fatty acid or fatty acid halide, such as the chloride, with the appropriate amine or aminoalcohol as described in Abadij et al, *J. Med. Chem.*, **37**, 1889-93 (1994) while all esters may be

synthesized by the reaction with the appropriate alcohols. 1- and 2-arachidonylglycerols may be prepared by a modification of the procedure established by Serdarevich et al, *J. Lipid Res.*, **7**, 277 (1966) for the synthesis of fatty acid monoglycerides. Radioactively labeled fatty acid ethanolamides may be prepared by the reaction of acid chlorides (Nu-Check Prep, Elysian, MN) with [³H]ethanolamine (10-30 Ci/mmol; American Radiolabeled Chemicals, St. Louis) as described in Desarnad, *J. Biol. Chem.*, **270**, 6030 (1995). All compounds may be purified by HPLC or flash column chromatography, and their identities may be established by NMR and/or gas chromatography-mass spectrometry. Exploration of the Y and Z pharmacophores shows that compounds containing primary, secondary and tertiary amido groups as well as hydroxyethyl ester or glycerol ester moieties are capable of competing with [³H]anandamide, but exhibit a wide range of potencies. Structural variations of the head group Z leads to analogs with diverse selectivities for the anandamide transporter. Thus substitution of the terminal hydroxyl with a hydrogen causes a substantial decrease in potency, whereas replacement of the entire hydroxyalkyl moiety with hydrogen yields compounds that are as potent as anandamide. Introduction of a methyl group alpha to the amido nitrogen also leads to active compounds. Chiral molecules display considerable enantioselective inhibition of [³H]anandamide transport. The (*S*) enantiomer is approximately four times more potent than its (*R*) isomer.

To study the effects of head group conformational preference, a set of analogs was prepared in which the head group is partially restricted by incorporation into five- or six-member rings. The resulting 3- and 4-hydroxypiperidinyl- and 3-hydroxypyrrolidinyl- amides, which were tested as racemic pairs, have activities for the transporter similar to that of anandamide. Another cyclic head group analog, having both the amido nitrogen and an ether oxygen restricted into a morpholine ring maintains considerable activity (approximately half that of anandamide), indicating that the hydrogen in the hydroxyl head group may not be necessary for interaction with the transporter.

The most striking structure-activity correlation was observed with analogs having hydroxyphenyl radicals at the head group. Use of the hydroxyphenyl group leads to relatively potent uptake inhibitors, with the 4-hydroxyphenyl analog being distinctly the most successful. Conversely, the 4-methylphenyl analog as well as other analogs with electron donating or electron withdrawing para substituents display no significant activity. Varying these substituents from the para to the meta or ortho position does not restore activity. Other analogs containing multiple substituents on the phenyl ring (e.g., 3-chloro-4-hydroxyphenyl) or a bulkier aromatic moiety [e.g., 1-(4-hydroxynaphthyl)] are also less potent than the 4-hydroxyphenyl group.

The transporter.

In order to properly evaluate the effectiveness of inhibitors of anandamide transport, it was necessary to establish the identity and character of the carrier-

mediated transporter. The accumulation of radioactively labeled exogenous [³H]anandamide by neurons and astrocytes fulfills several criteria of a carrier-mediated transport. It is a rapid process that reaches 50% of its maximum within about four minutes. Furthermore, [³H]anandamide accumulation is temperature dependent and saturable. Kinetic analyses reveals that accumulation in neurons can be represented by two components of differing affinities (lower affinity: Michaelis constant, $K_m = 1.2 \mu\text{M}$, maximum accumulation rate, $V_{\text{max}} = 90.9 \text{ pmol/min per milligram of protein}$; higher affinity: $K_m = 0.032 \mu\text{M}$, $V_{\text{max}} = 5.9 \text{ pmol/min per milligram of protein}$). The higher affinity component may reflect a binding site, however, as it is displaced by the cannabinoid receptor antagonist, SR-141716-A (100 nM). In astrocytes, [³H]anandamide accumulation is represented by a single high-affinity component ($K_m = 0.32 \mu\text{M}$, $V_{\text{max}} = 171 \text{ pmol/min per milligram of protein}$). Such apparent K_m values are similar to those of known neurotransmitter uptake systems and are suggestive therefore of high-affinity carrier-mediated transport.

To characterize further this putative anandamide transporter, cortical astrocytes in culture were employed. As expected from a selective process, the temperature-sensitive component of [³H]anandamide accumulation was prevented by nonradioactive anandamide, but not by palmitoyl ethanolamide, arachidonate, prostanoids, or leukotrienes. Replacement of extracellular sodium ion with N-dimethylglucosamine or choline had no effect suggesting that accumulation is mediated by a Na^+ - independent mechanism which has been observed for other lipids. Moreover, inhibition of fatty acid

amide hydrolase (FAAH) activity indicates that an anandamide hydrolysis does not provide the driving force for anandamide transport into astrocytes within the time frame of the experiment. Finally, the cannabinoid receptor agonist WIN-55212-2 (1 μ M) and antagonist SR-141716-A (10 μ M) also had no effect, suggesting that receptor internalization was not involved.

A primary criterion for defining carrier-mediated transport is pharmacological inhibition. To identify inhibitors of anandamide transport, examination was made of various components that prevent the cellular uptake of other lipids such as fatty acids, phospholipids or bromocresol green. Among the compounds tested, only bromocresol green interfered with inanimate transport, albeit with limited potency and partial efficacy, bromocresol green inhibited [3 H]anandamide accumulation with an IC₅₀ (concentration needed to produce half-maximal inhibition) of 4 μ M in neurons and 12 μ M in astrocytes and acted noncompetitively. Moreover, bromocresol green had no significant effect on the binding of [3 H]WIN-55212-2 to rat cerebral membranes, on FAAH activity in brain microsomes and on uptake of [3 H]arachidonate or [3 H]ethanolamine in astrocytes.

The bromocresol green, which blocks PGE₂ transport, raised the question of whether anandamide accumulation occurred by means of a PGE₂ carrier. That this is not the case was shown by the lack of [3 H]PGE₂ accumulation in neurons or astrocytes and by the inability of PGE₂ to interfere with [3 H]anandamide accumulation. Previous

results indicating that expression of PGE₂ transporter mRNA in brain tissue is not detectable further support this conclusion.

[³H]anandamide Transport Assay.

For standard transport assays, confluent astrocytoma cells grown in 90-mm plates were incubated at 37°C in 10 ml of Tris-Krebs' buffer containing 10 - 50 x 10⁶ dpm/ml of the radioactive tracers of the test compounds (unless indicated otherwise, specific radioactivity was 0.31 - 0.69 mCi/mmol). At various times after the addition of tracer (0 - 20 min), 1-ml samples of the incubation media were collected for liquid scintillation counting. Under these conditions, clearance of radioactive material from the incubating medium provides an accurate estimate of transport into cells, as indicated both by previous work with rat brain neurons (2) and by preliminary experiments with astrocytoma cells.

The cells were incubated for 4 min at 37°C in the presence of 10 - 500 nM anandamide containing 0.05 - 2.5 nM [³H]anandamide. Nonspecific accumulation (measured at 0 - 4°C) was subtracted before determining kinetic constants by Lineweaver-Burke analysis.

A minimum of three independent experiments conducted in triplicate was used to define the concentration needed to produce half-maximal inhibition (IC₅₀) for each compound. IC₅₀ values were obtained by nonlinear least-squares fitting of the data, using the PRIZM software package. All other experiments were carried out in triplicate

and repeated at least twice with identical results. The formulae and IC₅₀ values of exemplary inhibitors are set forth in Table I with the first formula being anandamide and AA being the arachidonyl radical. Data are expressed as mean \pm SEM.

Table I














Structure	IC ₅₀
 ethanolamide	15.1 ± 3.0
 ethanolamide	13.0 ± 3.6
 ethanolamide	10.6 ± 1.5
 ethanolamide	14.1 ± 1.2
 ethanolamide	18.3 ± 4.2
 ethanolamide	10.5 ± 1.2
AA  NH-C ₂ H ₅	48.5 ± 7.3
AA  NH ₂	9 ± 2
AA  O-C ₄ H ₉ OH	6.7 ± 0.8
AA 	18.5 ± 0.7

Table I (continued)

Structure	IC ₅₀
	48.5 ± 8.1
	37.7 ± 0.7
	10.4 ± 1.2
	2.2 ± 0.2
	21.3 ± 3.4
	25
	10.0 ± 0.2
	15
	15.3 ± 3.0

Table I (continued)

Structure	IC ₅₀
2,2-dimethyl-AA 	7.6 ± 1.2
2,2-dimethyl-AA 	33.2 ± 4.2
2,2-dimethyl-AA 	16.5 ± 1

[³H]Anandamide Transport in Astrocytoma Cells.

As expected of a carrier-mediated process, [³H]Anandamide accumulation in human astrocytoma cells is rapid ($t_{1/2}$ = 3 min), temperature dependent and saturable, displaying an apparent Michaelis constant (K_m) of $0.6 \pm 0.1 \mu\text{M}$ and a maximal accumulation rate (V_{max}) of $14.7 \pm 0.15 \text{ pmol/min per mg of protein}$ ($n = 5$). The accumulation is not affected by replacement of Na^+ with choline, indicating that it is mediated by a Na^+ -independent mechanism. In addition, [³H]anandamide accumulation is prevented by the anandamide transport inhibitor *N*-(4-hydroxyphenyl)-arachidonamide with a IC_{50} value of $2.2 \pm 0.2 \mu\text{M}$, whereas its positional isomer *N*-(3-hydroxyphenyl)-arachidonamide is 10 times less effective ($\text{IC}_{50} = 21.3 \pm 3.4$).

Some of the inhibitors have been identified as competitive since they are recognized as substrates by the transporter and will undergo membrane translocation.

The IC_{50} data in Table I provide the affinity data for ligand recognition by the anandamide transporter, but do not provide information on whether the ligands also may serve as substrates for the transporter. To investigate substrate translocation we used a representative set of radioactively labeled compounds. We first tested three key analogs that compete with anandamide for uptake: [3H]arachidonamide, [3H]N-(4-hydroxyphenyl)arachidonamide, the most potent competitor in our series, and [3H]2-arachidonylglycerol. As shown in Fig. 4, the [3H]2-arachidonylglycerol (squares) and [3H]N-(4-hydroxyphenyl)arachidonamide (diamonds) analogs are transported as rapidly and effectively as [3H]anandamide (circles). These findings suggest that the anandamide transporter also may participate in the inactivation of 2-arachidonylglycerol, which was thought to be primarily mediated by enzymatic hydrolysis. In agreement with this possibility, kinetic analyses indicate that [3H]2-arachidonylglycerol is accumulated in astrocytoma cells with an apparent K_m of $0.7 \pm 0.1 \mu M$ and a V_{max} of 28 ± 6 pmol/min per mg of protein, values that are comparable to those obtained with [3H]anandamide in the same cell preparation ($n = 3$).

Fig. 5 shows the effects of modifications in the hydrophobic tail. In this study, in addition to [3H]arachidonamide (empty squares), we tested one cis-triene analog [3H]cis-eicosatrienoyl ethanolamide (empty circles) one cis-diene analog [3H]cis-eicosadienoyl ethanolamide (triangles), and two cis monounsaturated analogs with the double bond located in the middle of the carbon chain, [3H]cis-eicosaenoyl ethanolamide

(full squares), and [^3H]oleylethanolamide (full circles). Although all of these fatty acid ethanolamides are able to compete with [^3H]anandamide for transport, only [^3H]arachidonamide is effectively transported into cells. Of the remaining compounds, the cis-triene and the cis-diene are transported very slowly ($t_{1/2} \approx 20$ min), whereas the two monoalkenes are not transported at all. [^3H]Palmitylethanolamide, a saturated acid ethanolamide that may activate an as-yet-uncharacterized peripheral CB2-like receptor, is not transported to any significant extent. These findings indicate the existence of two distinct sets of structural requirements in the function of the anandamide transporter, one for substrate recognition and another for substrate translocation.

Modifications of the hydrophobic fatty acid tail reveal unexpectedly distinct requirements for recognition and translocation of substrates by the anandamide transporter. Substrate recognition requires the presence of at least one cis double bond situated at the middle of the fatty acid chain, pointing to a preference for ligands in which the hydrophobic tail can fold in the middle and adopt a bent U-shaped conformation. Indeed, analogs with fully saturated chains or those incorporating trans double bonds do not interact significantly with the transporter. By contrast, substrate translocation requires a minimum of four cis nonconjugated double bonds, as ligands containing one, two, or three olefins are transported either very slowly or not at all. This finding suggests that for transmembrane transport to occur substrates must be capable of adopting a tightly folded conformation, one that is not energetically favorable for ligands containing an insufficient number of cis double bonds.

Molecular modeling studies of fatty acid ethanolamides differing in the degree of unsaturation of their hydrophobic carbon chains provides insight into these distinctive conformational requirements. Possible low-energy conformers of these molecules are significantly different. The presence of one or more nonconjugated cis double bonds in the middle of the chain leads to the formation of a turn that brings in closer proximity the head and tail of the molecule. The shape of this turn is determined by the number and position of the cis double bonds. Conversely, the introduction of a central trans double bond yields a more extended chain conformation and hinders the ability of the molecule to undergo folding. Thus one of the low-energy conformers of anandamide displays a folded hairpin shape with the two halves of the molecule facing each other. The cis-triene analog may adopt an analogous conformation, though one that is wider than that of anandamide. The width of the turn increases considerably in the cis-dienes and the two monoalkenes due to the marked increase in distance between the head group and tail of the molecule. In the corresponding trans alkene analog, the distance between the head and tail is much greater. It is important to point out that, whereas anandamide like arachidonic acid may adopt either a closed-hairpin or a U-shaped conformation depending on the properties of the surrounding milieu, the hairpin conformation may be thermodynamically unfavorable to fatty acid ethanolamides containing only one or two double bonds.

A plausible interpretation of our results is that recognition and translocation of substrates by the anandamide transporter are governed by distinct conformational preferences. Although the initial recognition step may require that substrates assume a bent U-shaped conformation of variable width, the subsequent step of translocation across the cell membrane may impose a more tightly folded hairpin conformation.

A "therapeutically effective amount" of a compound, as used herein, is the quantity of a compound which, when administered to an individual or animal, results in a sufficiently high level of anandamide in the individual or animal to cause a discernable increase or decrease in a cellular activity affected or controlled by cannabinoid receptors. For example, anandamide can stimulate receptor-mediated signal transduction that leads to the inhibition of forskolin-stimulated adenylate cyclase (Vogel *et al.*, *J. Neurochem.* 60:352 (1993)). Anandamide also causes partial inhibition of N-type calcium currents via a pertussis toxin-sensitive G protein pathway, independently of cAMP metabolism (Mackie *et al.*, *Mol. Pharmacol.* 47:711 (1993)).

A "therapeutically effective amount" of an anandamide inhibitor can also be an amount which results in a sufficiently high level of anandamide in an individual or animal to cause a physiological effect resulting from stimulation of cannabinoid receptors. Physiological effects which result from cannabinoid receptor stimulation include analgesia, decreased nausea resulting from chemotherapy, sedation and increased appetite. Other physiological functions include relieving intraocular pressure in glaucoma patients and suppression of the immune system. Typically, a

"therapeutically effective amount" of the compound ranges from about 10 mg/day to about 1,000 mg/day.

As used herein, an "individual" refers to a human. An "animal" refers to veterinary animals, such as dogs, cats, horses, and the like, and farm animals, such as cows, pigs, guinea pigs and the like.

The compounds of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical). The form in which the compounds are administered will be determined by the route of administration. Such forms include, but are not limited to, capsular and tablet formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular or subcutaneous administration and slow releasing microcarriers (for rectal, intramuscular or intravenous administration). The formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives. Suitable physiologically acceptable vehicles may include saline, sterile water, Ringer's solution, and isotonic sodium chloride solutions. The specific dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the individual being treated.

Example 1 - Effects of N-(4-hydroxyphenyl)-arachidonamide on anandamide-induced inhibition of adenylyl cyclase activity in cortical neurons

Cortical neurons were prepared in 12-well plates and used after 4 to 6 days in vitro. Incubations were carried out in the presence of forskolin (3 μ M) and isobutyl methyl xanthine (1mM). The cAMP concentrations were measured by radioimmunoassay with a commercial kit (Amersham, Arlington, IL) and following manufacturer's instructions. Fig. 1 reports the results when the neurons were stimulated with forskolin (3 μ M) in the presence of anandamide (0.001 to 3 μ M; open circles), anandamide (0.001 to 3 μ M) plus inhibitor N-(4-hydroxyphenyl)-arachidonamide (10 μ M) (filled circles), anandamide (3 μ M) plus SR-141716-A (1 μ M) (square), or anandamide (0.3 μ M) plus the inhibitor (10 μ M) and SR-141716-A (1 μ M) (triangle).

Example 2 - Effects of anandamide transport inhibitors on anandamide-induced inhibition of adenylyl cyclase activity

Forskolin (FSK)-stimulated neurons were separately incubated with inhibitors N-(4-hydroxyphenyl)-arachidonamide, (Sample AM404), N-(3-hydroxyphenyl)-arachidonamide (Sample AM403), and bromocresol green (each at 10 μ M) without (FSK alone) or with (FSK + anandamide) 0.3 μ M anandamide. The results are shown in Fig. 2, expressed as mean \pm SEM of nine independent determinations. One asterisk indicates $P < 0.05$ and two asterisks $P < 0.01$ (ANOVA followed by Bonferoni test).

The amount of cAMP in the presence of a concentration of WIN-55212-2 below threshold (1 nM, determined in preliminary experiments) were $96.7 \pm 2.5\%$ of forskolin alone and were not significantly affected by 10 μM of 404 ($89.8 \pm 2.6\%$), 10 μM of 403 ($92.4 \pm 2.3\%$), or 10 μM bromcresol green ($92.9 \pm 2.3\%$) ($n = 3$). In the presence of a concentration of glutamate below the threshold (3 μM), cAMP concentrations were $91.6 \pm 2\%$ of forskolin alone and were not significantly affected by 404 ($84.4 \pm 4.9\%$), 403 ($89.5 \pm 2.4\%$), or bromcresol green ($84.4 \pm 3\%$) ($n = 3$).

The transport inhibitor AM404 bound to CB1 receptors with low affinity ($K_i = 1.8 \mu\text{M}$) and did not reduce cAMP concentrations when applied at 10 μM . Nevertheless, the drug enhanced the effects of anandamide, increasing the potency (by a factor of 10) and decreasing the threshold (by a factor of 1.100), an effect that was prevented by SR-141716-A. Thus, a concentration of anandamide that was below threshold when applied alone (0.3 μM) produced an almost maximal effect when applied with AM404. Bromcresol green and inhibitor AM403, which were less effective than AM404 in inhibiting anandamide transport, were also less effective in enhancing the anandamide response. Furthermore, the decreases in cAMP concentrations produced by WIN-55212-2 (which stimulates CB1 receptors but is not subject to physiological clearance) or glutamate (which stimulates metabotropic receptors negatively coupled to adenylyl cyclase and is cleared by a selective transporter) are not affected by any of the anandamide transport inhibitors tested.

Example 3 - Effects of Sample AM404 on the analgesic activity of anandamide in the hot plate test.

The hot plate test (55.5°C) was carried out on male Swiss mice (25 to 30 g, Nossan, Italy) followed standard procedures [F. Porreca, H.L. Mosberg, R. Hurst, V.J. Hruby, T.F. Burke, *J. Pharmacol. Exp. Ther.* **230**, 341 (1994)]. Anandamide and AM404 were dissolved in 0.9% NaCl solution containing 20% dimethyl sulfoxide and injected intravenously at 20 mg/kg and 10 mg/kg, respectively. To determine whether cannabinoid receptors participate in the effect of anandamide, we administered anandamide (20 mg/kg, subcutaneously) to two groups of six mice each. In mice that received anandamide alone, latency to jump increased from 21.7 ± 1.5 s to 30.7 ± 0.8 s ($P < 0.05$, ANOVA) 20 min after injection. In contrast, in mice that received anandamide plus SR141716-A, the latency to jump was not affected (19.5 ± 3.1 s).

Three groups of six mice received Sample 404 (10 mg/kg, intravenous), anandamide (20 mg/kg, intravenous), or anandamide plus 404. The hot plate test (55.5°C) was performed at the times indicated, and latency to jump (in seconds) was measured before (control) and after the drugs were injected. In all groups, latency to jump before injections was 21 ± 0.6 s ($n = 18$). A fourth group of mice received injections of vehicle alone (saline containing 20% dimethyl sulfoxide), which did not affect latency to jump. One asterisk indicates $P < 0.05$ compared with uninjected controls (ANOVA followed by Bonferroni test), and one cross indicates $P < 0.01$

compared with anandamide-treated animals (Student's *t* test). Results are set forth in Fig. 3.

Intravenous anandamide (20 mg. per kilogram of body weight) elicited a modest but significant analgesia, as measured by the hot plate test ($P < 0.05$ Student's *t* test); this analgesia disappeared 60 min after injection and was prevented by SR-141716-A. Administration of AM404 (10 mg/kg, intravenously) had no antinociceptive effect within 60 min of injection but significantly enhanced and prolonged anandamide-induced analgesia ($P < 0.01$, Student's *t* test).

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the invention.

Claims:

1. A method of inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a compound represented by the following structural formula:



and physiologically acceptable salts thereof, wherein:

X is a hydrophobic aliphatic hydrocarbon chain containing from about 4 to about 30 carbon atoms and having one or more nonconjugated cis double bonds in the middle portion of the chain;

Y is selected from the group consisting of amide and ester radicals; and

Z is selected from the group consisting of hydrogen, lower alkyl, hydroxy substituted lower alkyl, aryl, hydroxy substituted aryl, heterocyclic and hydroxy substituted heterocyclic radicals.

2. The method of claim 1 wherein Z is a polar nonionizable group containing a hydroxy moiety at its distal end.

3. The method of claim 1 wherein Y is an amide radical.

4. The method of claim 1 wherein Y is an ester radical.

5. The method of claim 1 wherein X has two or more nonconjugated double bonds.
6. The method of claim 1 wherein X has at least four nonconjugated double bonds.
7. The method of claim 1 wherein Z is a hydroxy substituted aryl group.
8. The method of claim 1 wherein Z includes an alkyl group alpha to the amido nitrogen.
9. The method of claim 1 wherein Z is an (S) isomer of a chiral molecule.
10. A method of modifying the rate of anandamide inactivation in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of an inhibitor that targets an individual's or animal's anandamide transporter, said transporter being a protein exhibiting a temperature-dependent, saturable, high affinity and Na⁺-independent mechanism.
11. The method of claim 10 wherein the transporter-targeted inhibitor is an anandamide analog having a nonionizable head group containing a hydroxyl moiety at its distal end and a hydrophobic tail having a bent U-shaped stereochemical configuration.

12. A pharmacological formulation comprising a compound represented by the following structural formula:



and physiologically acceptable salts thereof, wherein:

X is a hydrophobic aliphatic hydrocarbon chain containing from about 4 to about 30 carbon atoms and having one or more nonconjugated cis double bonds in the middle portion of the chain;

Y is selected from the group consisting of amide and ester radicals;

Z is selected from the group consisting of hydrogen, lower alkyl, hydroxy substituted lower alkyl, aryl, hydroxy substituted aryl, heterocyclic and hydroxy substituted heterocyclic radicals; and

an inert carrier for the compound.

13. The formulation of claim 12 wherein Z is a polar nonionizable group containing a hydroxy moiety at its distal end.

14. The formulation of claim 12 wherein Y is an amide radical.

15. The formulation of claim 12 wherein Y is an ester radical.

16. The formulation of claim 12 wherein X has two or more nonconjugated double bonds.

17. The formulation of claim 12 wherein X has at least four nonconjugated double bonds.

18. The formulation of claim 12 wherein Z is a hydroxy substituted phenyl aryl group.

19. The formulation of claim 12 wherein Z includes an alky group alpha to the amido nitrogen.

20. The formulation of claim 12 wherein Z is an (S) isomer of a chiral molecule.




Fig 1.




Fig 2




Fig 3




Fig 4




Fig 5

Type a plus sign (+) inside this box - [+]

DECLARATION <input checked="" type="checkbox"/> Declaration Submitted with Initial Filing OR <input type="checkbox"/> Declaration Submitted after Initial Filing	0010/PTO Rev. 6/95	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket Number	UCON/141/US
			First Named Inventor	Alexandros Makriyannis
			COMPLETE IF KNOWN	
			Application Number	
			Filing Date	June 9, 1999
			Group Art Unit	
			Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Inhibitors of the Anandamide Transporter as Analgesic Agents

(Title of the Invention)

the specification of which

☒ is attached hereto

OR

☐ was filed on (MM/DD/YYYY) _____ as United States Application or PCT International Application Number _____ and was amended on (MM/DD/YYYY) _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Copy Attached?	
				Yes	No
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.
60/088,568	06/09/98	

DECLARATION

Page 2

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the registered practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Firm Name: **Alix, Yale & Ristas, LLP**Customer Number **002543**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor☐ A petition has been filed for this unsigned inventor

Given Name	Alexandros	Middle Initial		Family Name	Makriyannis	Suffix	
Inventor's Signature					Date		
RESIDENCE: City	Storrs	State	CT	Country	USA	Citizenship	USA
POST OFFICE ADDRESS	University of Connecticut , U-2092						
City	Storrs	State	CT	Zip	06269	Country	USA
						Applicant Authority	

Name of Additional Joint Inventor, if any:☐ A petition has been filed for this unsigned inventor

Given Name	Sonyuan	Middle Initial		Family Name	Lin	Suffix	
Inventor's Signature					Date		
RESIDENCE: City	Niantic	State	MA	Country	USA	Citizenship	China
POST OFFICE ADDRESS	6 Great Rock Circle						
City	Niantic	State	MA	Zip	01760	Country	USA
						Applicant Authority	

☒ Additional inventors are being named on supplemental sheet(s) attached hereto.

Name of Additional Joint Inventor, if any:										[] A petition has been filed for this unsigned inventor											
Given Name		Daniele				Middle Initial				Family Name		Piomelli				Suffix					
Inventor's Signature											Date										
RESIDENCE: City			San Diego				State		CA		Country		USA		Citizenship		Italy				
POST OFFICE ADDRESS			10640 John J. Hopkins Drive																		
City		San Diego			State		CA		Zip		92121		Country		USA		Applicant Authority				
[X] Additional inventors are being named on supplemental sheet(s) attached hereto.																					

656000-2423230